Mindray, a global provider of medical devices and solutions, introduced high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, which are aimed at diversifying its portfolio of cardiac biomarkers for cardiovascular disease diagnosis and management.
While cardiovascular disease is the leading cause of death worldwide, early detection is key in saving lives. Guidelines recommend the use of cTnl and NT-proBNP as essential biomarkers for suspected acute coronary syndrome (ACS) and heart failure in early screening, risk stratification, rapid diagnosis, and therapeutic monitoring.
The two assays are the collaborative effort of Mindray and HyTest, a Mindray company and a global provider of antibodies and antigens. HyTest, known for its cardiac biomarker expertise, had its cardiac troponin complex material selected as the international troponin standard by AACC in 2004.
Validated by Wuhan Asian Heart Hospital in China and Hennepin Healthcare Research Institute in the U.S., both assays showcase improved clinical performance, the company says.
Mindray hs-cTnI Assay for Myocardial Injury Detection
Mindray’s hs-cTnI assay surpasses the minimum requirements for hs-cTn by achieving a 93% detection rate between LoD and 99th URL and an imprecision CV below 5% at the 99th URL, the company says.
This demonstrates the assay’s sensitivity, precision, and reliability in detecting myocardial injury. Furthermore, a 0-2h diagnostic algorithm study conducted at the Hennepin Healthcare Research Institute further supports its effectiveness in diagnosing and managing cardiac conditions within this crucial timeframe.
Mindray NT-proBNP Assay with High Precision
NT-proBNP is an established cardiac marker for heart failure and its management. Mindray’s NT-proBNP assay demonstrates high precision with a CV of ≤5% and effectively minimizes interference from 55 common medications for heart diseases, proving reliability for heart failure detection and management, the company says.
“Through integrating HyTest’s pioneering antibodies and research on cardiac biomarkers with Mindray’s advanced reagent technology and platform, we will deliver more reliable solutions that bring improved patient outcomes in the field of cardiovascular diseases and beyond,” says Jianwen He, MD, PhD, chief scientific officer of Mindray IVD.